Rhenman Partners Asset Management Ab adds Abbott Laboratories (ABT) to its portfolio

Abbott Laboratories (ABT) : Rhenman Partners Asset Management Ab added new position in Abbott Laboratories during the most recent quarter end. The investment management firm now holds 84,100 shares of Abbott Laboratories which is valued at $3,780,295 , the company said in a statement filed on Aug 1, 2016 with the SEC.Abbott Laboratories makes up approximately 0.60% of Rhenman Partners Asset Management Ab’s portfolio.

Other Hedge Funds, Including , Cobiz Investment Management reduced its stake in ABT by selling 14,035 shares or 34.73% in the most recent quarter. The Hedge Fund company now holds 26,372 shares of ABT which is valued at $1,185,421. Abbott Laboratories makes up approx 0.29% of Cobiz Investment Management’s portfolio.Atlas Browninc. boosted its stake in ABT in the latest quarter, The investment management firm added 2,366 additional shares and now holds a total of 22,176 shares of Abbott Laboratories which is valued at $992,376. Abbott Laboratories makes up approx 0.40% of Atlas Browninc.’s portfolio.Advisory Services Network boosted its stake in ABT in the latest quarter, The investment management firm added 2,722 additional shares and now holds a total of 4,957 shares of Abbott Laboratories which is valued at $216,472. Abbott Laboratories makes up approx 0.05% of Advisory Services Network’s portfolio.Catawba Capital Management Va boosted its stake in ABT in the latest quarter, The investment management firm added 2,370 additional shares and now holds a total of 35,191 shares of Abbott Laboratories which is valued at $1,500,896. Abbott Laboratories makes up approx 0.35% of Catawba Capital Management Va’s portfolio.Cypress Asset Management Inctx reduced its stake in ABT by selling 225 shares or 1.2% in the most recent quarter. The Hedge Fund company now holds 18,543 shares of ABT which is valued at $790,859. Abbott Laboratories makes up approx 0.15% of Cypress Asset Management Inctx’s portfolio.

Abbott Laboratories closed down -0.14 points or -0.31% at $44.81 with 65,83,457 shares getting traded on Thursday. Post opening the session at $45.06, the shares hit an intraday low of $44.78 and an intraday high of $45.09 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.

Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.

Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *